Scarica l'app Stockscreener
25.23
1.06%
0.265
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$24.96
Aprire:
$24.93
Volume 24 ore:
1.57M
Relative Volume:
0.61
Capitalizzazione di mercato:
$3.19B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-12.43
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+6.77%
1M Prestazione:
+26.02%
6M Prestazione:
+31.00%
1 anno Prestazione:
-22.94%
Intervallo 1D:
$24.45
$25.27
Intervallo di 1 settimana:
$23.54
$25.52
Portata 52W:
$16.10
$35.70
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
25.23 | 3.16B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha
Natixis Sells 564,361 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Camber Capital Management LP Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Low Cost Wealth Building - earlytimes.in
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval - Yahoo Finance
Schroder Investment Management Group Grows Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What downside risks could hit Apellis Pharmaceuticals Inc. (1JK) stockRecession Risk & AI Optimized Trade Strategies - Newser
Why millennials buy Apellis Pharmaceuticals Inc. (1JK) stockPrice Action & High Accuracy Trade Alerts - Newser
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. (1JK) stock issue positive guidanceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock gets analyst attentionRate Cut & High Conviction Buy Zone Picks - Newser
Apellis’ EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases - Investing.com Nigeria
Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli - marketscreener.com
Apellis (APLS) Gains Boost from Positive Phase 3 Study Results - GuruFocus
Apellis’ EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals Announces Positive Phase 3 VALIANT Study Results for EMPAVELI in Treating C3 Glomerulopathy and Primary IC-MPGN - Quiver Quantitative
Transcript : Apellis Pharmaceuticals, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02 - marketscreener.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally stronglyMarket Performance Summary & AI Powered Market Entry Ideas - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock could be top winnerJuly 2025 Summary & High Yield Equity Trading Tips - Newser
38,572 Shares in Apellis Pharmaceuticals, Inc. $APLS Purchased by Wealthedge Investment Advisors LLC - MarketBeat
Will Apellis Pharmaceuticals Inc. stock deliver long term returnsAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight - GlobeNewswire Inc.
Virtus Investment Advisers LLC Acquires 12,106 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Steward Partners Investment Advisory LLC Buys 18,800 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Geode Capital Management LLC Raises Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pitches High-Growth Story At A Discounted Price - Finimize
Breakout Watch: How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peers2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Apellis Pharmaceuticals, Inc. $APLS Position Increased by Rhenman & Partners Asset Management AB - MarketBeat
Apellis Pharmaceuticals (APLS) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trading the Move, Not the Narrative: (APLS) Edition - news.stocktradersdaily.com
Can Sanmitra Commercial Limited Maintain Its Strong Profit MarginsInterest Rate Changes & High Yield Investment Portfolio - earlytimes.in
Apellis Pharmaceuticals, Inc. $APLS Stock Position Decreased by SG Americas Securities LLC - MarketBeat
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals (Nasdaq: APLS) to Webcast Investor Chats at 2025 Conferences - Stock Titan
Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch - MSN
9 Oversold Biotech Stocks to Invest In - Insider Monkey
FY2025 Earnings Estimate for APLS Issued By Zacks Research - MarketBeat
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesShare Buyback & AI Powered Market Entry Ideas - newser.com
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):